Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Pre-Tax Margin

Income before tax as a percentage of revenue.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to -55.8%

Pre-tax margin was -55.8% in Q2 FY2026, down 12.4 pp from a year earlier. On a trailing-twelve-month basis it was -20.8%, up 38.3 pp year over year. Over 3 fiscal years it widened by 86.7 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-55.8%-27.6 pp QoQ
Last fiscal yearDec 2025
-21.5%+67.7 pp YoY
LTMJun 2026
-20.8%+38.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.4 pp——
1 year+67.7 pp——
3 years+86.7 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-21.5%
Year-over-year change
+67.7pp

Pre-Tax Margin vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 pre-tax margin of -20.8% is the 3rd highest of the 8 companies compared; the peer median is -54.7%.
  • Its year-over-year change of +38.3 pp is the 3rd highest of 7, against a peer median of +17.1 pp.
  • Over three fiscal years its change of +86.7 pp compares with a peer median of +196.8 pp.
ADPT Competitors Peer median
Pre-Tax Margin for ADPT and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202649.7% +1.3 pp-0.8 pp
LEGNLegend Biotech CorporationLTM Sep 20262.4% +26.8 pp+353.5 pp
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026-20.8% +38.3 pp+86.7 pp
ZLABZai Lab LimitedLTM Jun 2026-42.4% +7.3 pp+167.4 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+411.7 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-62.2% +4313.7 pp+63.2 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-103.3% -81.1 pp+226.3 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-72563.2% ——
IRONDisc Medicine, Inc.FY2025— ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding ADPT) -54.7%+17.1 pp+196.8 pp

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.